Media Thread, page-15793

I like many here am dismayed at the stagnant share price for a company we know that has a huge potential to change the face of cancer care with its IP.

Management is gearing this company for sale because that's what they've done with the other biotech companies they primed.

However, with IMU why don't they think differently. Be more ambitious. With such IP, they can think bigger. Keep IP in house. Develop it in house. Produce, manufacture and sell the treatment as a stand alone company. Yes it means developing many other aspects of this biotech company , but if we just think bigger we can be so much more than just selling the IP , because that is what was historically done. Why porn it off to Big Pharma when IMU can become the new BP. They can be the new CSL if they change tact.

The other point to note here is IMUs success will put a huge dent in the current SOC chemotherapy protocols which generate billions for Big Pharma. A part of me feels there is something at play aswell to keep IMU down because of the ground breaking potential it has in changing the face of oncological care and humanity.

I'm synical of Big Pharma to say the least. They wouldn't want IMU ti succeed soon because it will dramatically affect all the current oncological drugs on offer and hence BPs bottom line.

We need to see the light and think differently. There is so much hope here for millions of people. IMU owes it to itself, to Prof, Yunan Fong, to the share holders and to the very people whose lives they aim to uplift, to develop all the IP to its absolute full potential, and it can be done in house. Just have the tenacity to think differently, think bigger. If we do this we can reach $ value share price because we're value adding to the company.

We live in hope.

Good luck to all term share holders patiently following and investing in this company.

Mr. Paul Hopper don't treat this company like an investment property. Own it, develop and nuture it to its full potential.

DYOR

Opinion only.